Information Provided By:
Fly News Breaks for November 19, 2019
TAK, PHAT
Nov 19, 2019 | 08:13 EDT
Needham analyst Alan Carr initiated coverage of Phathom Pharmaceuticals (PHAT) with a Buy rating and $40 price target. The analyst is positive on the company's development of vonoprazan, a "novel oral potassium-competitive acid blocker for the treatment of Erosive Esophagitis and H. pylori infection", noting that its 2015 launch by Takeda (TAK) in Japan has demonstrated benefits over standard of care proton pump inhibitors in both indications. Having licensed the rights from Takeda, the analyst adds that the company's initiated Phase 3 trials in Erosive Esophagitis and H. pylori infection for registration in the U.S., Canada, and Europe, projecting a U.S. launch in 2022 and and U.S. peak sales of $1.9B-$2.0B in 2032.
News For PHAT;TAK From the Last 2 Days
PHAT
Mar 26, 2024 | 08:19 EDT
Phathom Pharmaceuticals announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer campaign, "VOQUEZNA Can Kick Some Acid," to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. "Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day. Although Erosive GERD is a highly symptomatic condition that can have a detrimental impact on millions of patients, there has been little medical innovation in this category in decades, until now," said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals. "We believe our new DTC campaign is accessible, memorable, and informative. Our goal is to connect with people unsatisfied with their current treatment options and empower them to explore the power of VOQUEZNA with their healthcare provider."